Surmodics | SRDX - Equity Capital And Reserves


Surmodics reported $118.9M in Equity Capital and Reserves for its fiscal quarter ending in September of 2024.





Equity Capital And Reserves Change Date
Abbott USD 50.83B 0 Sep/2025
Align Technology USD 3.96B 44.68M Sep/2025
Anika Therapeutics USD 146.8M 867K Sep/2025
Arrowhead Research USD 568.42M 102.37M Dec/2025
Baxter International USD 7.24B 79M Sep/2025
Boston Scientific USD 22.65B 235M Sep/2025
EDAP TMS EUR 27.82M 13.07M Jun/2025
Edwards Lifesciences USD 10.2B 340.3M Sep/2025
Haemonetics USD 911.45M 62.28M Dec/2025
Heron Therapeutics USD 14.88M 42.14M Sep/2025
J&J USD 78.47B 0 Sep/2025
Merit Medical Systems USD 1.53B 41.36M Sep/2025
Mesa Laboratories USD 186.69M 8.22M Dec/2025
Nektar Therapeutics USD 85.09M 109.3M Sep/2025
Option Care Health USD 1.36B 1.29M Sep/2025
Stryker USD 21.78B 594M Sep/2025
Surmodics USD 118.9M 753K Sep/2024
Trinity Biotech USD -54.72M 5.18M Sep/2025